Advanced search
Publication Cover
The American Journal of Drug and Alcohol Abuse
Encompassing All Addictive Disorders
Volume 43, 2017 - Issue 5
Submit an article Journal homepage
265
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

Naltrexone in the treatment of binge eating disorder in a patient with severe alcohol use disorder: a case report

Arnaud LeroyUniv. Lille, CNRS, UMR 9193 - SCALab - Cognitive & Affective Sciences Laboratory, Lille, France;Psychiatry and Addiction Medicine, CHU Lille, Lille, FranceCorrespondence[email protected]
, MD, Msc,
Louise CartonPharmacology, CHU Lille, Lille, France
, MD, Msc,
Harry GomajeePsychiatry and Addiction Medicine, CHU Lille, Lille, France
, MD,
Regis BordetPharmacology, CHU Lille, Lille, France
, MD, PhD &
Olivier CottencinUniv. Lille, CNRS, UMR 9193 - SCALab - Cognitive & Affective Sciences Laboratory, Lille, France;Psychiatry and Addiction Medicine, CHU Lille, Lille, France
, MD, PhD
Pages 618-620 | Received 08 Dec 2016, Accepted 18 Feb 2017, Published online: 16 Mar 2017

References

  • Collins PY, Patel V, Joestl SS, March D, Insel TR, Daar AS. Grand challenges in global mental health. Nature 2011 Jul 6;475:27–30.
  • Zindel LR, Kranzler HR. Pharmacotherapy of alcohol use disorders: seventy-five years of progress. J Stud Alcohol Drugs Suppl 2014;75:79–88.
  • Franck J, Jayaram-Lindström N. Pharmacotherapy for alcohol dependence: status of current treatments. Curr Opin Neurobiol 2013 Aug;23:692–699.
  • Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2010 Dec 8;12:CD001867.
  • NICE. Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence [Internet]. 2011 Available from: https://www.nice.org.uk/guidance/cg115/chapter/1-guidance
  • FDA. FDA approves weight-management drug Contrave. 2014.
  • Neumeister A, Winkler A, Wöber-Bingöl C. Addition of naltrexone to fluoxetine in the treatment of binge eating disorder. Am J Psychiatry 1999 May;156:797.
  • Piquet-Pessôa M, Fontenelle LF. Opioid antagonists in broadly defined behavioral addictions: a narrative review. Expert Opin Pharmacother 2016;17:835–844.
  • Rebello CJ, Greenway FL. Reward-induced eating: therapeutic approaches to addressing food cravings. Adv Ther 2016 Nov;33:1853–1866.
  • Cyr M, Wang Z, Tau GZ, Zhao G, Friedl E, Stefan M, et al. Reward-based spatial learning in teens with bulimia nervosa. J Am Acad Child Adolesc Psychiatry 2016 Nov;55:962–71.e3.
  • Nutt DJ, Lingford-Hughes A, Erritzoe D, Stokes PRA. The dopamine theory of addiction: 40 years of highs and lows. Nat Rev Neurosci 2015 May;16:305–312.
  • Chen RZ, Huang R-RC, Shen C-P, MacNeil DJ, Fong TM. Chronic administration of nalmefene leads to increased food intake and body weight gain in mice. Eur J Pharmacol 2004 Jul 8;495:63–66.
  • Ma Y-Y, Meng L, Guo C-Y, Han J-S, Lee DY-W, Cui C-L. Dose- and time-dependent, context-induced elevation of dopamine and its metabolites in the nucleus accumbens of morphine-induced CPP rats. Behav Brain Res 2009 Dec 1;204:192–199.
  • Aboujaoude E, Salame WO. Naltrexone: a pan-addiction treatment? CNS Drugs 2016 Aug;30:719–733.
  • Toneatto T, Brands B, Selby P. A randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of concurrent alcohol use disorder and pathological gambling. Am J Addict 2009 Jun;18:219–225.
  • Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addict Abingdon Engl 2013 Feb;108:275–293.
  • Yoon G, Kim SW, Petrakis IL, Westermeyer J. High-dose naltrexone treatment and gender in alcohol dependence. Clin Neuropharmacol. 2016 Aug;39:165–168.
  • Malcolm R, O’Neil PM, Sexauer JD, Riddle FE, Currey HS, Counts C. A controlled trial of naltrexone in obese humans. Int J Obes 1985;9:347–353.
  • Haile CN, Kosten TA, Kosten TR. Pharmacogenetic treatments for drug addiction: alcohol and opiates. Am J Drug Alcohol Abuse 2008;34:355–381.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.